<DOC>
	<DOCNO>NCT00638378</DOCNO>
	<brief_summary>This clinical trial orally administer Ruxolitinib ( INCB018424 ) patient whose disease progress follow 1 prior chemotherapy regimen ( include anti-androgens ketoconazole ) metastatic , androgen-independent prostate cancer .</brief_summary>
	<brief_title>Study Ruxolitinib ( INCB018424 ) Administered Orally Patients With Androgen Independent Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Diagnosed radiographicallydocumented metastatic prostate cancer progress receive androgensuppressive therapy form bilateral orchiectomy GonadotropinReleasing Hormone ( GnRH ) agonist ( eg , leuprolide , goserelin ) . Patients must demonstrate evidence progressive disease base 1 follow criterion : 1 ) Progressive measurable disease , 2 ) Progressive rise prostatespecific antigen ( PSA ) level ( 2 consecutive rise prior reference level ) , 3 ) Development new lesion bone scan . If receive GnRH agonist primary hormonal therapy , serum testosterone level must ≤ 50 ng/mL . Must receive progress follow 1 prior chemotherapy regimen metastatic disease ( include antiandrogen ketoconazole ) ; , must discontinue prior systemic therapy poor tolerance adverse effect ; , must refuse chemotherapy treatment . Patients undergone 1 prior chemotherapy regimen may admit discretion sponsor . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Baseline serum PSA level ≥ 10 ng/mL Received anticancer medication 30 day receive first dose study medication except GnRH agonists bisphosphonates . Any unresolved toxicity great equal Grade 2 previous anticancer therapy , except stable chronic toxicity expect resolve , peripheral neurotoxicity .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>